Aperture Technologies

Aperture Therapeutics is a biotechnology company focused on developing small molecule therapeutics for neurodegenerative and neurodevelopmental disorders. Launched by Apple Tree Partners (ATP), the company leverages a deep understanding of the dual-leucine zipper kinase (DLK) and leucine zipper-bearing kinase (LZK) pathways, which are critical mediators of neuronal stress responses. Aperture's lead programs target Huntington's disease and other CNS conditions where neuronal degeneration is a primary driver. By inhibiting these kinases, the company aims to provide neuroprotective benefits and slow disease progression in patients with limited treatment options.